Sanofi (XSWX:SAN) Stock Based Compensation: CHF0 Mil (TTM As of Dec. 2025)


XSWX:SAN Sanofi SA XSWX:SAN
87 GF Score
Price CHF73.20
GF Value CHF104.30
! 2 Warning Signs
View Full Analysis

What is Sanofi Stock Based Compensation?

Sanofi XSWX:SAN 87 Stock Based Compensation is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:SAN with a GF Score™ of 87/100 and a GF Value™ of CHF104.30. The stock has 2 warning signs investors should review.

Sanofi's Stock Based Compensation for the six months ended in Dec. 2025 was CHF0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0 Mil.

Sanofi Stock Based Compensation Related Terms

Sanofi Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Sanofi's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Stock Based Compensation Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:SAN
87GF Score
Sanofi SA XSWX:SAN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0 Mil.

What does a Stock Based Compensation of CHF0 Mil mean?
Sanofi (XSWX:SAN) has a Stock Based Compensation of CHF0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sanofi and its competitors.
Is Sanofi's Stock Based Compensation too high?
Sanofi's current Stock Based Compensation is CHF0 Mil. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Stock Based Compensation compare to LLY and JNJ?
Sanofi's Stock Based Compensation of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sanofi and its competitors. Sanofi's current Stock Based Compensation is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Stock Based Compensation of CHF0 Mil. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current Stock Based Compensation is CHF0 Mil. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Stock Based Compensation is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.

Key valuation signals for XSWX:SAN:

  • Stock Based Compensation: CHF0 Mil
  • GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score

Get the complete analysis for XSWX:SAN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF104.30
GF Value